Series AHealthUnited StatesJun 08, 2026

Kanvas Biosciences raises $48.0M Series A (United States, Jun 2026)

$48.0M
$48 million Series A
Browse investors in United States →
Generated social card
Kanvas Biosciences social card
Headline

Kanvas Biosciences raises $48 million to advance microbiome cancer therapies - Cornell Chronicle

About

Kanvas Biosciences is focused on developing microbiome-based cancer therapies, leveraging a breakthrough imaging platform to map the gut microbiome. The company aims to improve cancer immunotherapy outcomes and address malnutrition-related gut diseases, with its foundational technology emerging from research at Cornell University.

Article summary

Kanvas Biosciences raises $48 million to advance microbiome cancer therapies  Cornell Chronicle

Founder
Hao Shi
Co-founder
Investors · 2
DCVCLead
FUND
Lions Capital
FUND
Related rounds
Jun 09, 2026Impulse Space$500.0MSeries DUnited States
Jun 08, 2026Haast Autonomous$1.9MPre-seedUnited States
Jun 08, 2026Ilant Health$15.0MSeries AUnited States
Jun 08, 2026Reset$6.0MSeedUnited States
Kanvas Biosciences raises $48.0M Series A (United States, June 2026) | Datapile